KRAS and non-small cell lung carcinoma: We first addressed the effects of these inhibitors alone in the NSCLC lines A549 (K-Ras mutant), HCC827 (EGFR mutant) and H3122 (EML4-ALK translocated), representing the three most frequent oncogenic genotypes of the disease, to establish concentration frames for the target inhibition.